background
sever
ill
patient
novel
coronaviru
infect
progress
rapidli
acut
respiratori
failur
aim
select
use
prognost
factor
sever
ill
incid
method
studi
prospect
includ
patient
infect
treat
beij
ditan
hospit
januari
januari
prognost
factor
sever
ill
select
lasso
cox
regress
analys
predict
sever
ill
probabl
pneumonia
predict
accuraci
evalu
concord
index
calibr
curv
decis
curv
clinic
impact
curv
result
neutrophiltolymphocyt
ratio
nlr
identifi
independ
risk
factor
sever
ill
patient
infect
nlr
cindex
confid
interv
calibr
curv
fit
well
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
coronaviru
larg
viru
famili
known
caus
common
cold
seriou
ill
middl
east
respiratori
syndrom
mer
sever
acut
respiratori
syndrom
sar
found
novel
coronaviru
caus
unexplain
viral
pneumonia
wuhan
china
decemb
recogn
world
health
organ
januari
follow
month
transmit
hubei
provinc
throughout
china
even
countri
caus
confirm
case
februari
patient
novel
coronaviru
infect
mild
moder
ill
often
experienc
dyspnea
one
week
sever
ill
patient
progress
rapidli
acut
respiratori
failur
acut
respiratori
distress
syndrom
metabol
acidosi
coagulopathi
septic
shock
earli
identif
risk
factor
sever
ill
facilit
appropri
support
care
promptli
access
intens
care
unit
icu
necessari
mild
patient
gener
isol
symptomat
treatment
avail
icucar
need
unless
condit
worsen
rapidli
reduc
mortal
allevi
shortag
medic
resourc
aim
compar
clinic
characterist
imag
featur
treatment
outcom
patient
mild
moder
sever
infect
explor
use
prognost
factor
accur
individu
assess
sever
incid
infect
studi
prospect
singlecent
studi
includ
patient
infect
treat
beij
ditan
hospit
januari
januari
diagnosi
pneumonia
clinic
classif
accord
new
coronaviru
pneumonia
diagnosi
treatment
plan
trial
version
develop
nation
health
committe
peopl
republ
china
http
wwwnhcgovcn
clinic
classif
follow
mild
fever
respiratori
tract
symptom
imag
show
pneumonia
moder
meet
follow
respiratori
distress
respiratori
rate
beat
min
b
rest
state
mean
oxygen
satur
c
arteri
blood
oxygen
partial
pressur
oxygen
concentr
sever
one
follow
condit
respiratori
failur
occur
requir
mechan
ventil
b
shock
occur
c
icu
admiss
requir
combin
organ
failur
studi
approv
ethic
committe
beij
ditan
hospit
patient
sign
inform
consent
suspect
infect
patient
taken
upper
respiratori
throat
swab
sampl
admiss
store
viru
transport
medium
transport
beij
cdc
laboratori
diagnosi
influenza
viru
influenza
b
viru
bacteri
fungal
detect
sputum
respiratori
secret
perform
hospit
epidemiolog
histori
comorbid
vital
sign
symptom
sign
record
detail
laboratori
test
includ
biochem
indic
blood
routin
creactiv
protein
chest
radiograph
ct
scan
admiss
patient
reexamin
laboratori
index
imag
examin
record
symptom
sign
treatment
outcom
event
endpoint
studi
sever
ill
develop
age
day
repres
median
rang
categor
variabl
number
laboratori
data
mean
interquartil
rang
cutoff
valu
neutrophiltolymphocyt
ratio
nlr
calcul
base
maximum
youden
index
compar
differ
two
group
ttest
chisquar
test
mannwhitney
u
test
lasso
cox
regress
use
select
independ
risk
factor
affect
outcom
analys
perform
use
spss
statist
packag
spss
inc
chicago
il
usa
r
version
use
establish
nomogram
calibr
decis
curv
clinic
impact
curv
pvalu
consid
statist
signific
patient
infect
includ
studi
diagnos
mild
mild
group
moder
sever
sever
group
admiss
median
age
two
group
statist
differ
mild
group
year
old
sever
group
year
old
none
patient
histori
huanan
seafood
market
exposur
wuhan
left
beij
recent
close
exposur
histori
pneumonia
patient
patient
wuhan
citizen
visit
wuhan
recent
signific
differ
diabet
cardiovascular
diseas
chronic
obstruct
pulmonari
diseas
two
group
patient
hypertens
sever
group
mild
group
p
tabl
among
case
case
fever
case
high
fever
case
dyspnea
case
mild
short
breath
patient
sever
group
cough
sputum
product
fatigu
case
gastrointestin
symptom
blood
neutrophil
count
sever
group
significantli
higher
mild
group
blood
lymphocyt
count
serum
sodium
chlorin
level
significantli
lower
rate
bacteri
infect
significantli
increas
tabl
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
median
day
ill
onset
admiss
day
group
patient
isol
admiss
patient
receiv
antivir
treatment
patient
receiv
oseltamivir
mg
everi
h
oral
patient
receiv
lopinavir
ritonavir
tablet
mg
twice
daili
oral
nearli
half
patient
receiv
antibiot
therapi
patient
sever
group
receiv
antibiot
therapi
one
patient
receiv
methylprednisolon
day
admiss
stop
admiss
anoth
patient
took
methylprednisolon
mg
everi
day
ten
month
optic
neuromyel
continu
take
admiss
patient
sever
group
receiv
oxygen
support
nebul
inhal
therapi
patient
receiv
noninvas
ventil
receiv
invas
mechan
ventil
nebul
inhal
drug
includ
recombin
human
interferon
acetylcystein
end
jan
patient
die
patient
discharg
remain
patient
hospit
patient
progress
sever
ill
still
icu
tabl
variabl
includ
lasso
regress
result
show
age
nlr
hypertens
obtain
case
cohort
predict
factor
sever
ill
incid
partial
likelihood
devianc
smallest
nlr
signific
factor
lambda
standard
error
figur
three
factor
mention
includ
multivari
cox
regress
analys
result
show
age
nlr
predict
factor
howev
hazard
ratio
hr
age
close
age
transform
categor
variabl
year
year
base
cutoff
valu
three
variabl
includ
cox
regress
analys
final
nlr
select
use
prognost
factor
affect
prognosi
sever
ill
incid
forward
select
procedur
nomogram
establish
base
nlr
use
predict
nosever
ill
surviv
rate
figur
nomogram
cindex
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
confid
interv
ci
predict
sever
ill
probabl
calibr
curv
show
predict
rate
agreement
actual
result
observ
cohort
figur
decis
curv
clinic
impact
curv
show
nlr
superior
standard
net
benefit
influenc
outcom
patient
figur
use
receiv
oper
characterist
analysi
predict
valu
nlr
incid
sever
ill
compar
mulbsta
model
result
show
nlr
highest
area
curv
auc
higher
sensit
specif
two
model
tabl
median
followup
time
day
minimum
day
maximum
day
patient
divid
two
strata
accord
cutoff
valu
nlr
low
risk
high
risk
age
age
year
age
year
kaplanmei
analysi
show
signific
statist
differ
two
group
p
p
figur
furthermor
patient
pneumonia
stratifi
sever
ill
incid
respect
age
nlr
strata
age
year
nlr
strata
age
year
nlr
strata
age
year
nlr
strata
age
year
nlr
sever
ill
case
strata
strata
case
strata
case
strata
shown
figur
sever
ill
incid
significantli
differ
strata
p
differ
strata
signific
p
sinc
outbreak
pneumonia
decemb
new
confirm
patient
everi
day
china
number
sever
case
death
also
increas
day
day
research
show
patient
receiv
icu
care
mortal
number
patient
wuhan
region
increas
rapidli
current
difficulti
shortag
medic
resourc
especi
critic
care
resourc
sever
case
identifi
earli
possibl
risk
stratif
manag
help
allevi
insuffici
medic
resourc
might
reduc
mortal
risk
predict
model
sever
ill
pneumonia
publish
date
pneumonia
patient
hospit
wuhan
patient
pneumonia
earli
onset
sever
median
time
onset
admiss
sever
patient
mild
patient
similar
sever
patient
deterior
day
ill
cours
develop
sever
pneumonia
acut
respiratori
failur
sever
death
patient
infect
mostli
old
age
comorbid
studi
sever
ill
one
year
old
decreas
lymphocyt
count
relat
progress
diseas
propos
blood
lymphocyt
relat
index
may
potenti
predictor
nlr
wide
use
marker
assess
sever
bacteri
infect
prognosi
patient
pneumonia
tumor
increas
nlr
indic
poor
clinic
prognosi
result
indic
may
act
lymphocyt
lymphocyt
damag
import
factor
caus
patient
deterior
addit
patient
sever
ill
might
bacteri
infect
due
low
immun
function
latest
report
follow
laboratori
test
result
patient
infect
found
patient
rise
neutrophil
count
fall
lymphocyt
count
death
studi
data
patient
pneumonia
analyz
baselin
characterist
patient
mild
sever
group
describ
compar
dynam
chang
laboratori
index
imag
demonstr
independ
risk
factor
affect
incid
sever
ill
screen
result
show
nlr
signific
factor
affect
sever
ill
incid
signific
predict
valu
furthermor
accord
nlr
age
stratif
incid
sever
ill
one
nlr
age
year
old
age
nlr
patient
previou
studi
show
mulbsta
score
earli
warn
mortal
viral
pneumonia
includ
six
indic
age
smoke
histori
hypertens
bacteri
coinfect
lymphopenia
multilobular
infiltr
score
wide
use
evalu
mortal
patient
communityacquir
pneumonia
studi
nlr
compar
mulbsta
score
model
result
show
nlr
higher
auc
cindex
sensit
specif
indic
nlr
better
two
model
earli
predict
incid
sever
ill
furthermor
found
predict
effect
nlrmulbsta
model
better
origin
model
nlr
easytous
predictor
index
base
result
suggest
patient
pneumonia
improv
risk
stratif
manag
accord
nlr
age
model
patient
age
year
old
nlr
risk
treat
commun
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
hospit
home
isol
patient
age
year
old
nlr
low
risk
need
gener
isol
ward
patient
age
nlr
patient
moder
risk
admit
isol
ward
respiratori
monitor
support
care
patient
age
nlr
high
risk
activ
transfer
icu
invas
respiratori
support
equip
figur
largescal
case
risk
stratif
manag
help
allevi
shortag
medic
resourc
reduc
mortal
critic
patient
limit
studi
first
studi
singl
center
small
sampl
extern
valid
cohort
second
patient
still
hospit
whose
condit
mayb
chang
followup
studi
includ
final
surviv
outcom
howev
focus
earli
identif
critic
case
risk
stratif
manag
expect
risk
model
help
allevi
shortag
medic
resourc
manag
patient
pneumonia
nlr
use
prognost
factor
affect
prognosi
sever
ill
patient
pneumonia
earli
applic
nlr
age
benefici
patient
classif
manag
relief
medic
resourc
shortag
author
declar
conflict
interest
regard
public
paper
